Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

被引：0

作者：

Lassen, U. N. ^{[1
]}

Albert, C. M. ^{[2
]}

Kummar, S. ^{[3
]}

van Tilburg, C. M. ^{[4
,5
]}

Dubois, S. G. ^{[6
]}

Geoerger, B. ^{[7
]}

Mascarenhas, L. ^{[8
]}

Federman, N. ^{[9
]}

Schilder, R. J. ^{[10
]}

Doz, F. ^{[11
,12
]}

Berlin, J. D. ^{[13
]}

Oh, D-Y. ^{[14
]}

Bielack, S. S. ^{[15
]}

McDermott, R. ^{[16
]}

Tan, D. S. ^{[17
]}

Cruickshank, S. ^{[18
]}

Ku, N. C. ^{[18
]}

Cox, M. C. ^{[18
]}

Drilon, A. ^{[19
]}

Hong, D. S. ^{[20
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Finsen Ctr,Phase Unit 1, Copenhagen, Denmark

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Childrens Hosp, Pediat Oncol, Seattle, WA 98195 USA

[3] Stanford Univ, Stanford Canc Inst, Med Oncol, Stanford, CA 94305 USA

[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr, NCT Heidelberg KiTZ, Pediat Oncol, Heidelberg, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] Dana Farber Boston Childrens Canc & Blood Disorde, Pediat Oncol, Boston, MA USA

[7] Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France

[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Oncol, Los Angeles, CA 90033 USA

[9] Univ Calif Los Angeles, Pediat Oncol, Los Angeles, CA USA

[10] Thomas Jefferson Univ, Med Oncol, Philadelphia, PA 19107 USA

[11] Inst Curie, Pediat Oncol, Paris, France

[12] Univ Paris 05, Paris, France

[13] Vanderbilt Ingram Canc Ctr, Med, Nashville, TN USA

[14] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[15] Klinikum Stuttgart, Pediat Oncol, Olgahosp, Stuttgart, Germany

[16] AMNCH Adelaide & Meath Hosp, Med Oncol, Dublin, Ireland

[17] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[18] Loxo Oncol, Clin Dev, San Francisco, CA USA

[19] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[20] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

409O

引用

页码：133 / 133

页数：1

共 50 条

[41] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
Rieke, D. T.
Hong, D. S.
Drilon, A.
Tan, D. S.
Lin, J.
Kummar, S.
McDermott, R.
Berlin, J.
Italiano, A.
Lassen, U. N.
Leyvraz, S.
Tahara, M.
Norenberg, R.
Burcoveanu, D. -I.
Brega, N.
Shen, L.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 142 - 143
[42] EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER: AN EXTENDED FOLLOW-UP
Zwaan, C. Michel
Van Tilburg, Cornelis
Doz, Francois
Albert, Catherine
Blattmann, Claudia
Geoerger, Birgit
Dubois, Steven
Federman, Noah
Mascarenhas, Leo
Nagasubramanian, Rama
Pappo, Alberto
Watt, Tanya
Norenberg, Ricarda
Dima, Laura
De la Cuesta, Esther
Laetsch, Theodore
Xu, Ruihua
PEDIATRIC BLOOD & CANCER, 2022, 69 : S324 - S325
[43] Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Hong, D. S.
Xu, R-H.
McDermott, R. S.
Shen, L.
Dierselhuis, M. P.
Doz, F.
Tahara, M.
Bernard-Gauthier, V.
Norenberg, R.
Brega, N.
Laetsch, T. W.
Drilon, A.
ANNALS OF ONCOLOGY, 2023, 34 : S469 - S469
[44] Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Drilon, A. E.
Xu, R-H.
van Tilburg, C. M.
Doz, F.
Tan, D. S. W.
Lin, J. J.
Geoerger, B.
Zwaan, C. M.
Lassen, U. N.
Italiano, A.
Kummar, S.
McDermott, R. S.
Burcoveanu, D-I.
Neu, N.
Brega, N.
Laetsch, T.
Hong, D. S.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S500 - S501
[45] Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
Drilon, Alexander E.
Hong, David S.
Van Tilburg, Cornelis Martinus
Doz, Francois
Tan, Daniel S. W.
Kummar, Shivaani
Lin, Jessica Jiyeong
McDermott, Raymond S.
Zwaan, C. Michel
Norenberg, Ricarda
Fellous, Marc Mardoche
Brega, Nicoletta
Xu, Rui-Hua
Laetsch, Theodore Willis
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
Hong, David S.
Drilon, Alexander E.
Tan, Daniel Shao-Weng
Lin, Jessica Jiyeong
Kummar, Shivaani
McDermott, Raymond S.
Berlin, Jordan
Italiano, Antoine
Lassen, Ulrik Niels
Leyvraz, Serge
Tahara, Makoto
Norenberg, Ricarda
Burcoveanu, Domnita-Ileana
Brega, Nicoletta
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
Andre, T.
Hong, D.
Deeken, J.
Italiano, A.
Liu, T.
Burcoveanu, D.
Norenberg, R.
Mussi, C.
Xu, R.
Drilon, A.
Shen, L.
ANNALS OF ONCOLOGY, 2023, 34 : S12 - S13
[48] LONG-TERM FOLLOW-UP OF THE EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER
Federman, Noah
Van Tilburg, Cornelis
Dierselhuis, Miranda
Albert, Catherine
Geoerger, Birgit
Dubois, Steven
Mascarenhas, Leo
Nagasubramanian, Ramamoorthy
Pappo, Alberto
Watt, Tanya
Bernard-Gauthier, Vadim
Norenberg, Ricarda
De la Cuesta, Esther
Doz, Francois
Zhang, Yizhuo
PEDIATRIC BLOOD & CANCER, 2023, 70
[49] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
McDermott, R. S.
van Tilburg, C.
Lin, J. J.
Kummar, S.
Tan, D. S. W.
Albert, C. M.
Berlin, J. D.
Lassen, U. N.
Doz, F.
Geoerger, B.
Mascarenhas, L.
Federman, N.
Norenberg, R.
Dima, L.
Mussi, C.
De La Cuesta, E. A.
Laetsch, T.
Hong, D. S.
Drilon, A. E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S751 - S752
[50] ESMO Congress 2018-Extended Data for Larotrectinib confirm Efficacy and Safety in adult and pediatric Patients with TRK fusion-related Cancers, regardless of Tumor Type
Bayer, A. G.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) : 797 - 797

← 1 2 3 4 5 →